Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- Male and female age 18 and above

- Diagnosed with active rheumatoid arthritis (RA) by standard criteria at least 16 weeks
before screening, have functional ACR class I-III

- Have an inadequate response to methotrexate

- In addition to an inadequate response to methotrexate have an inadequate response or
intolerance to 1 but not more than 2 TNF inhibitors

- Have a minimum of 6 swollen and 6 tender joints (from 66/68 joint count)

- Have hsCRP of ≥ 0.8 mg/dL (8mg/L) [by central laboratory values] or an ESR ≥ 28 mm/hr

- Willing to use effective birth control for the entire length of the study

Exclusion Criteria:

- Diagnosed with juvenile Rheumatoid Arthritis

- Have been treated with other biologic treatment than a TNF inhibitor

- Active systemic bacterial, viral or fungal infection or evidence of prior or current
Hepatitis B or C infection or HIV infection, latent bacterial, viral or fungal
infections

- Have been treated with Intramuscular or Intra-articular glucocorticosteroids within 4
weeks of randomization

- Taking Oral steroids at dose above 10 mg/day of prednisone (or prednisone equivalents)

- Have other autoimmune disease other than RA like lupus, multiple sclerosis

- Have significant concurrent medical condition at the time of screening or baseline
visit